Global Somatic Cancer Mutation Testing Market Size & Trends 
                     Global Somatic Cancer Mutation Testing Market Size & Trends 
According to a new market research report published by Global Market Estimates, the Global
Somatic Cancer Mutation Testing Market is projected to grow at a CAGR of 9.5% from
2022 to 2027.
The growing demand for clinical diagnostic testing for cancer mutations, increasing adoption
of NGS in cancer diagnostics,  growing demand for genetic  mutation diagnostics,  and the
advancements  in  medical  diagnostic  technologies  have  been  instrumental  in  the  rapid
development of the global somatic cancer mutation testing market.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-
depth TOC on “Global Somatic Cancer Mutation Testing Market - Forecast to 2027’’
https://www.globalmarketestimates.com/market-report/somatic-cancer-mutation-
testing-market-3886 
By  Product  (Instruments  &  Platforms,  Reagents  &  Other  Consumables),  By  Type
(Hematological Cancer Profiling, Solid Tumor Profiling), By Technology (NGS, PCR & RT
PCR, IHC, Others), By Indication (Breast Cancer, Ovarian, Prostate, Lung Cancer, Others),
By Region (North America, Asia Pacific, Central & South America, Europe, and the Middle
East  &  Africa),  End-User  Landscape  Analysis,  Company  Market  Share  Analysis,  and
Competitor Analysis
Key Market Insights
 As per the indication outlook, the breast cancer segment is expected to be the largest
segment in the somatic cancer mutation testing market from 2022 to 2027
 The Asia Pacific region is analyzed to be the fastest-growing segment in the market
 United States has the largest share in the North American market during the forecast
period of 2022-2027. 
 As per the type,  the hematological  cancer  profiling segment  is  expected to be the
largest segment in the somatic cancer mutation testing market from 2022 to 2027
 Thermo Fisher Scientific, Inc., Illumina, Inc., Invitae Corporation, F. Hoffmann-La
Roche  Ltd.,  MedGenome,  CENTOGENE  N.V.,  Myriad  Genetics,  Inc.,  eviCore
healthcare,  CeGaT GmbH, QIAGEN, among others,  are  key players in the global
somatic cancer mutation testing market.
Product Outlook (Revenue, USD Billion, 2022-2027)
 Instruments & Platforms
 Reagents & Other Consumables
Type Outlook (Revenue, USD Billion, 2022-2027)
 Hematological Cancer Profiling
 Solid Tumor Profiling
Technology Outlook (Revenue, USD Billion, 2022-2027)
 NGS
 PCR & RT PCR
 IHC
 Others
Indication Outlook (Revenue, USD Billion, 2022-2027)
 Breast Cancer
 Ovarian
 Prostate
 Lung Cancer
 Others
Regional Outlook (Revenue, USD Billion, 2022-2027)
North America
 The U.S.
 Canada
 Mexico
Europe
 Germany
 UK
 France
 Spain
 Italy
 Netherlands
 Rest of Europe
Asia Pacific
 China
 India
 Japan
 South Korea
 Thailand
 Indonesia
 Malaysia
 Singapore
 Vietnam
 Rest of APAC
Central & South America
 Brazil
 Argentina
 Chile
 Rest of CSA
Middle East & Africa
 Saudi Arabia
 UAE
 Israel
 South Africa
 Rest of MEA
Contact: Yash Jain
Email address: [email protected]
Phone Number: +1 6026667238